| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics |
1
Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, Georgia 30322 [S. H., N. S.], and The Kapiolani Health Research Institute and the University of Hawaii, Honolulu, Hawaii 96813 [R. K. W.]
Phenylacetate (PA) is a member of a class of aromatic fatty acids that has demonstrated antitumor activity in experimental models and in humans. Previous reports have shown that PA and its analogues can act as ligands for the peroxisome proliferator-activated receptor (PPAR) and thereby regulate certain gene expression through peroxisome proliferator response elements. The role of this activity in the antitumor activity of PA has not been determined. To address this question, we have used the human neuroblastoma cell line LA-N-5, which expresses PPAR
and can be induced to differentiate with PA and with classical PPAR
ligands. Our results indicated that the PPAR
ligands 15-deoxy-
prostaglandin J2 and GW1929 as well as PA induced LA-N-5 cells to differentiate to a similar phenotype as evidenced by inhibition of cell proliferation, neurite outgrowth, increased acetylcholinesterase activity, and decreased N-myc gene expression. Furthermore, induction with all of the compounds was accompanied by up-regulation of mRNA levels of the nuclear retinoic acid receptor ß (RARß) and specific activation of a reporter gene construct (
SVßRE-CAT) that contains the canonical RA response element located in the RARß promoter. All of the assessed functional and molecular effects of PA on LA-N-5 cells, as well as those of the classical PPAR
ligands, were inhibited by cotreatment with specific PPAR
antagonists (GW9662 and/or GW0072). Taken together, these studies have confirmed a role for PPAR
in neuroblastoma cell biology and indicated that the PPAR
signaling pathway plays a direct role in the PA-induced differentiation response of this cell type.
This article has been cited by other articles:
![]() |
S. Han, J. D. Ritzenthaler, B. Wingerd, H. N. Rivera, and J. Roman Extracellular Matrix Fibronectin Increases Prostaglandin E2 Receptor Subtype EP4 in Lung Carcinoma Cells through Multiple Signaling Pathways: THE ROLE OF AP-2 J. Biol. Chem., March 16, 2007; 282(11): 7961 - 7972. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Peraza, A. D. Burdick, H. E. Marin, F. J. Gonzalez, and J. M. Peters The Toxicology of Ligands for Peroxisome Proliferator-Activated Receptors (PPAR) Toxicol. Sci., April 1, 2006; 90(2): 269 - 295. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Han, J. D. Ritzenthaler, H. N. Rivera, and J. Roman Peroxisome proliferator-activated receptor-{gamma} ligands suppress fibronectin gene expression in human lung carcinoma cells: involvement of both CRE and Sp1 Am J Physiol Lung Cell Mol Physiol, September 1, 2005; 289(3): L419 - L428. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Han, H. N. Rivera, and J. Roman Peroxisome Proliferator-Activated Receptor-{gamma} Ligands Inhibit {alpha}5 Integrin Gene Transcription in Non-Small Cell Lung Carcinoma Cells Am. J. Respir. Cell Mol. Biol., April 1, 2005; 32(4): 350 - 359. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. I. Johnsen, M. Lindskog, F. Ponthan, I. Pettersen, L. Elfman, A. Orrego, B. Sveinbjornsson, and P. Kogner Cyclooxygenase-2 Is Expressed in Neuroblastoma, and Nonsteroidal Anti-Inflammatory Drugs Induce Apoptosis and Inhibit Tumor Growth In vivo Cancer Res., October 15, 2004; 64(20): 7210 - 7215. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Konopleva, E. Elstner, T. J. McQueen, T. Tsao, A. Sudarikov, W. Hu, W. D. Schober, R.-Y. Wang, D. Chism, S. M. Kornblau, et al. Peroxisome proliferator-activated receptor {gamma} and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias Mol. Cancer Ther., October 1, 2004; 3(10): 1249 - 1262. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Han, N. Sidell, P. B. Fisher, and J. Roman Up-regulation of p21 Gene Expression by Peroxisome Proliferator-Activated Receptor {gamma} in Human Lung Carcinoma Cells Clin. Cancer Res., March 15, 2004; 10(6): 1911 - 1919. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. J. Kim, K. S. Park, S. Y. Chung, Y. Y. Sheen, D. C. Moon, Y. S. Song, K. S. Kim, S. Song, Y. P. Yun, M. K. Lee, et al. Peroxisome Proliferator-Activated Receptor-{gamma} Activator 15-Deoxy-{Delta}12,14-Prostaglandin J2 Inhibits Neuroblastoma Cell Growth through Induction of Apoptosis: Association with Extracellular Signal-Regulated Kinase Signal Pathway J. Pharmacol. Exp. Ther., November 1, 2003; 307(2): 505 - 517. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Han, H. Inoue, L. C. Flowers, and N. Sidell Control of COX-2 Gene Expression through Peroxisome Proliferator-Activated Receptor {gamma} in Human Cervical Cancer Cells Clin. Cancer Res., October 1, 2003; 9(12): 4627 - 4635. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. Clay, A. Monjazeb, J. Thorburn, F. H. Chilton, and K. P. High 15-Deoxy-{Delta}12,14-prostaglandin J2-induced apoptosis does not require PPAR{gamma} in breast cancer cells J. Lipid Res., November 1, 2002; 43(11): 1818 - 1828. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |